Rivaroxaban Shows Net Benefit for Acute Coronary Syndrome
FROM THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION
ATLAS ACS-2 TIMI 51 was sponsored by Johnson & Johnson and Bayer. Dr. Gibson said that he has been a consultant to those companies and to numerous other pharmaceutical companies; has served on the speakers bureaus for Daiichi Sankyo, Eli Lilly, and The Medicines Company; and has received fees for educational presentations on behalf of Daiichi Sankyo and Eli Lilly. He has received research grants from Johnson & Johnson and Bayer. Dr. Armstrong has been a consultant to Eli Lilly, Sanofi-Aventis, Bristol-Myers Squibb, Merck, Regado, Hoffmann-LaRoche, GlaxoSmithKline, Pfizer, and Takeda, and he has received grant support from Boehringer Ingelheim, Hoffman LaRoche, Sanofi-Aventis, Schering Plough, and Merck. Dr. Bhatt said that he has received grant support from AstraZeneca, Regado, Portola, and GlaxoSmithKline.
